Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218783 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
A Phase 3 study of Glaucoma and Cataract, sponsored by SpyGlass Pharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT07218783 is a Phase 3 study of Glaucoma and Cataract that is actively recruiting participants, run by SpyGlass Pharma. The registered enrollment target is 400 participants, below the 906-participant average among 92 other Glaucoma trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07218783, a Phase 3 study of Glaucoma and Cataract, is actively recruiting participants, sponsored by SpyGlass Pharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.
Conditions Studied
Interventions
- DRUG Bimatoprost Implant System
- DEVICE SpyGlass IOL
- DRUG Timolol Maleate Ophthalmic Solution, 0.5%
- DEVICE Commercial IOL
Study Locations (1)
Texas
- Houston Eye Associates - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2025-10-15 |
| Est. Completion | 2031-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07218783
The ClinicalTrials.gov registry entry for NCT07218783 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 906-participant average among 92 other Glaucoma trials with a reported enrollment target (56% lower). The listed sponsor is SpyGlass Pharma, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Glaucoma appearing as the primary indexed condition, and to 4 interventions - of which Bimatoprost Implant System is the first listed.
NCT07218783 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07218783 about?
NCT07218783 is a clinical study titled "Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)". This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.
What is the current status of trial NCT07218783?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2025-10-15. Estimated completion is 2031-03-31.
What conditions does trial NCT07218783 study?
This clinical trial studies the following conditions: Glaucoma, Cataract, Ocular Hypertension.
What interventions are being tested in trial NCT07218783?
The interventions under investigation include: Bimatoprost Implant System (DRUG), SpyGlass IOL (DEVICE), Timolol Maleate Ophthalmic Solution, 0.5% (DRUG), Commercial IOL (DEVICE).
Who is sponsoring clinical trial NCT07218783?
This trial is sponsored by SpyGlass Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07218783 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pilocarpine Use After Kahook Goniotomy
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
COMPLETED · Phase 3
-
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
-
Functional and Structural Imaging for Glaucoma
RECRUITING
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.